4. Intangible Assets, Goodwill and Other

9 Months Ended

Sep. 30, 2022

GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Changes to goodwill by segment are as follows (in millions):


	Life Science		Clinical Diagnostics		Total
Balances as of December 31, 2021:
Goodwill	$	333.3	$	349.2	$	682.5
Accumulated impairment losses	(41.8)		(293.4)		(335.2)
Goodwill, net	291.5		55.8		347.3

Acquisitions (see Note 2)	—		55.9		55.9


Currency fluctuations	—		(3.6)		(3.6)
Period increase, net	—		52.3		52.3

Balances as of September 30, 2022:
Goodwill	333.3		401.5		734.8
Accumulated impairment losses	(41.8)		(293.4)		(335.2)
Goodwill, net	$	291.5	$	108.1	$	399.6

Information regarding our identifiable purchased intangible assets with finite and indefinite lives is as follows (in millions):


	September 30, 2022
	Weighted-Average Remaining Amortization Period (years)	Purchase Price		Accumulated Amortization		Net Carrying Amount
Customer relationships/lists	5.13	$	99.2	$	(83.1)	$	16.1
Know how	3.00	158.9		(145.5)		13.4
Developed product technology	13.06	206.8		(115.6)		91.2
Licenses	6.11	58.2		(37.0)		21.2
Tradenames	6.81	5.9		(4.2)		1.7
Covenants not to compete	3.27	6.4		(3.7)		2.7


Total finite-lived intangible assets		535.4		(389.1)		146.3
In-process research and development		178.8		—		178.8
Total purchased intangible assets		$	714.2	$	(389.1)	$	325.1


	December 31, 2021
	Weighted-Average Remaining Amortization Period (years)	Purchase Price		Accumulated Amortization		Net Carrying Amount
Customer relationships/lists	5.27	$	111.8	$	(90.7)	$	21.1
Know how	3.75	171.6		(154.9)		16.7
Developed product technology	13.42	215.6		(115.6)		100.0
Licenses	6.79	64.9		(40.6)		24.3
Tradenames	7.33	6.3		(4.4)		1.9
Covenants not to compete	3.78	6.5		(2.9)		3.6


Total finite-lived intangible assets		576.7		(409.1)		167.6
In-process research and development		86.3		—		86.3
Total purchased intangible assets		$	663.0	$	(409.1)	$	253.9

Amortization expense related to purchased intangible assets is as follows (in millions):